A Novel Performance Metric for Device Companies
Executive SummaryReturn on invested capital, or ROIC, is a financial measurement that may correlate more strongly with a medical device company's stock performance than other metrics, such as EBITDA. A sample of 20 publicly traded pure-play device firms showed that while most of the companies control costs and maintain healthy cash flows, few firms focus on capital efficiency to build a platform for growth. Two case studies also make the point: Stryker's 1998 acquisition of Howmedica illustrates how difficult it may be to recover capital turnover, a measurement that is affected by activities that drive top-line revenue growth and assets, after a major acquisition. On the other hand, the recent financial history of Varian Medical, shows the positive effects of focusing on capital efficiency. The conclusion: Improving the rate of capital turnover should provide an opportunity to increase shareholder value.
You may also be interested in...
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.
While contract manufacturer ABH Nature' complied with consent decree, Sen. Chuck Schumer says FDA is late in enforcing against noncompliant firms across the supplement sector. Other recent consumer health recalls include more OTC ranitidine tablets due to the potential carcinogen NDMA found in the heartburn ingredient and four versions of Sure 48HR Anti-Perspirant & Deodorant with labeling errors.